PT - JOURNAL ARTICLE AU - Vitor Heidrich AU - Julia S. Bruno AU - Franciele H. Knebel AU - Vinícius C. de Molla AU - Wanessa Miranda-Silva AU - Paula F. Asprino AU - Luciana Tucunduva AU - Vanderson Rocha AU - Yana Novis AU - Celso Arrais-Rodrigues AU - Eduardo R. Fregnani AU - Anamaria A. Camargo TI - Dental biofilm microbiota dysbiosis is associated with the risk of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation AID - 10.1101/2021.02.04.21251019 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.04.21251019 4099 - http://medrxiv.org/content/early/2021/03/27/2021.02.04.21251019.short 4100 - http://medrxiv.org/content/early/2021/03/27/2021.02.04.21251019.full AB - Acute graft-versus-host disease (aGVHD) is one of the major causes of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recently, aGVHD onset was linked to intestinal microbiota (IM) dysbiosis. However, other bacterial-rich gastrointestinal sites, such as the mouth, which hosts several distinctive microbiotas, may also impact the risk of GVHD. The dental biofilm microbiota (DBM) is highly diverse and, like the IM, interacts with host cells and modulates immune homeostasis. We characterized changes in the DBM of patients during allo-HSCT and evaluated whether the DBM could be associated with the risk of aGVHD. DBM dysbiosis during allo-HSCT was marked by a gradual loss of bacterial diversity and changes in DBM genera composition, with commensal genera reductions and potentially pathogenic bacteria overgrowths. High Streptococcus and high Corynebacterium relative abundance at preconditioning were associated with a higher risk of aGVHD (67% vs. 33%; HR = 2.89, P = 0.04 and 73% vs. 37%; HR = 2.74, P = 0.04, respectively), while high Veillonella relative abundance was associated with a lower risk of aGVHD (27% vs. 73%; HR = 0.24, P < 0.01). Enterococcus faecalis bloom during allo-HSCT was observed in 20% of allo-HSCT recipients and was associated with a higher risk of aGVHD (100% vs. 40%; HR = 4.07, P < 0.001) and severe aGVHD (60% vs. 12%; HR = 6.82, P = 0.01). To the best of our knowledge, this is the first study demonstrating that DBM dysbiosis is associated with the aGVHD risk after allo-HSCT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementV.H. was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, process no. 13996-0/2018). V.C.M. was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, process no. 141575/2018-2). J.S.B. was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, process no. 001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Hospital Sírio-Libanês (approval number 1.414.217), in line with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data will be publicly available as soon as the peer-reviewed version of the manuscript is published.